GE HealthCare Technologies (GEHC) has had a rough year, and investors have been asking whether the selling is over, or whether more losses lie ahead.
Needham & Company gave investors their opinion on Sept. 22. The firm started coverage of GEHC with a Buy rating and a $93 price target, pointing to…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.